Search alternatives:
point decrease » point increase (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
point decrease » point increase (Expand Search)
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e point » _ point (Expand Search), 5 point (Expand Search), a point (Expand Search)
-
1501
-
1502
-
1503
-
1504
X-axis shows the MEHP quartiles, and Y-axis shows each hormone level.
Published 2014“…First quartile (≦5.90 ng/mL) is also compared to the 2nd (5.91–10.39 ng/mL), 3rd (10.40–15.30 ng/mL) and 4th (15.31+ ng/mL) quartile MEHP. …”
-
1505
-
1506
-
1507
-
1508
-
1509
-
1510
-
1511
-
1512
-
1513
-
1514
-
1515
-
1516
-
1517
-
1518
-
1519
Deseasonalized anomaly time series of temperature ((a), (b)) and precipitation minus evaporation (<em>P</em> − <em>E</em>) changes over the tropical oceans and the tropical land fo...
Published 2013“…The wet and dry regions are defined as the 30% highest and 70% lowest <em>P</em> − <em>E</em> grid points each month. Data are from the CMIP5 historical and RCP 4.5 simulations (1850–2100) and the AMIP simulations (1979–2008). …”
-
1520
Supplementary Material for: Hyperfunctioning Papillary Thyroid Carcinoma with a <b><i>BRAF</i></b> Mutation: The First Case Report and a Literature Review
Published 2021“…Subsequent mutational analysis of <i>BRAF</i> (exon 15), <i>TSHR</i> (exons 1–10), <i>GNAS</i> (exons 7–10), <i>EZH1</i> (exon 16), <i>KRAS</i>, <i>NRAS</i>, <i>HRAS</i> (codons 12, 13, and 61), and <i>TERT</i> promoter (C250T and C228T) identified a heterozygous point mutation in <i>BRAF</i> V600E in a tumor tissue sample. …”